Fig. 3. Current major antitumor approaches targeting M2-like TAMs to overcome tumor drug resistance.

These approaches mainly encompass three aspects: reducing the number of M2-like TAMs in the TME through direct or indirect methods, thereby diminishing their role in promoting tumor growth; using M2-like TAMs as antitumor drug delivery mediums; and inducing the re-polarization of M2-like TAMs to the M1 phenotype, thus restoring their anti-tumor activity and enhancing the immune response in the TME. These strategies collectively form a comprehensive therapeutic approach to overcoming tumor drug resistance by targeting M2 TAMs. (By Figdraw).